摘要
目的探讨中老年房颤患者脑卒中预防的现状及分析。方法对我院252例老年房颤患者资料进行回顾性调查,了解不同年龄层高危因素的分布,对比服用华法令和阿斯匹林等抗血栓药物后,患者脑卒中以及出血等并发症的发生率。结果高龄患者(≥75岁)的患者中,合并其他高危因素的机率比65-75岁组的患者显著增多;其中,48例接受华法令治疗,185例接受阿司匹林治疗;华法令组脑卒中发病率同阿司匹林组比较显著下降;华法令组并发非致死性出血机率显著高于阿司匹林组。结论老年房颤患者中,年龄本身是个高危因素,随着年龄增大,合并其他高危因素的几率增多;对于持续性老年房颤患者脑卒中的预防,华法令比阿司匹林效果明显,但临床实际应用中,华法令的使用率仍较低,且监测明显不足。
Objective To analyze current stroke prevention measures for elderly patients with atrial fibrillation. Methods A retrospective analysis was conducted of the clinical records of elderly patients with atrial fibrillation treated in our hospital within the recent 5 years. The distribution of high risk factors for different age levels was studied, and the incidence of stroke and complications such as hemorrhage were compared between patients treated with warfarin and aspirin therapy. Results Compared with patients of 65 to 75 years old, the incidence of complications with other high risk factors was increased in advanced age group （over 75 years）. Of these patients, 19.0% were treated with warfarin and 73.4% with aspirin. Compared with the aspirin group, stroke incidence was decreased significantly in warfarin group, which had simultaneously increased nonfatal hemorrhage. Conclusion Warfarin can be more effective than aspirin for stroke prevention in elderly patients with atrial fibrillation, but in clinical practice, the usage rate of warfarin still remains low with insufficient monitoring.
出处
《南方医科大学学报》
CAS
CSCD
北大核心
2006年第6期851-852,855,共3页
Journal of Southern Medical University
关键词
华法令
阿司匹林
脑卒中
房颤
warfarin
aspirin
Stroke
trial fibrillation
